We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Stryker (SYK) Q4 Earnings: Wall Street Forecasts for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Stryker (SYK - Free Report) to post quarterly earnings of $3.27 per share in its upcoming report, which indicates a year-over-year increase of 9%. Revenues are expected to be $5.6 billion, up 7.7% from the year-ago quarter.
Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Stryker metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Net Sales- Orthopaedics and Spine' will likely reach $2.31 billion. The estimate points to a change of +7.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- MedSurg and Neurotechnology' should come in at $3.29 billion. The estimate suggests a change of +7.9% year over year.
The collective assessment of analysts points to an estimated 'Net Sales- Orthopaedics and Spine- Knees' of $604.67 million. The estimate indicates a change of +9.5% from the prior-year quarter.
The consensus estimate for 'Net Sales- Orthopaedics and Spine- Spine' stands at $309.09 million. The estimate indicates a year-over-year change of +4.1%.
It is projected by analysts that the 'Geographic Revenue- International' will reach $1.49 billion. The estimate indicates a change of +10.8% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenue- United States' reaching $4.11 billion. The estimate indicates a year-over-year change of +6.5%.
Based on the collective assessment of analysts, 'Net Sales- Orthopaedics and Spine- United States' should arrive at $1.60 billion. The estimate suggests a change of +3% year over year.
Analysts predict that the 'Net Sales- Orthopaedics and Spine- Trauma and Extremities- United States' will reach $596.86 million. The estimate points to a change of +5.6% from the year-ago quarter.
Analysts forecast 'Net Sales- Orthopaedics and Spine- Knees- United States' to reach $449.97 million. The estimate points to a change of +8.4% from the year-ago quarter.
Analysts expect 'Net Sales- Orthopaedics and Spine- Hips- United States' to come in at $253.04 million. The estimate points to a change of +5.9% from the year-ago quarter.
The average prediction of analysts places 'Net Sales- Orthopaedics and Spine- Spine- International' at $81.72 million. The estimate indicates a change of +7.5% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Orthopaedics and Spine- International' will reach $694.57 million. The estimate points to a change of +15.8% from the year-ago quarter.
Over the past month, shares of Stryker have returned +2.9% versus the Zacks S&P 500 composite's +2.5% change. Currently, SYK carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Countdown to Stryker (SYK) Q4 Earnings: Wall Street Forecasts for Key Metrics
Wall Street analysts expect Stryker (SYK - Free Report) to post quarterly earnings of $3.27 per share in its upcoming report, which indicates a year-over-year increase of 9%. Revenues are expected to be $5.6 billion, up 7.7% from the year-ago quarter.
Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Stryker metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Net Sales- Orthopaedics and Spine' will likely reach $2.31 billion. The estimate points to a change of +7.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- MedSurg and Neurotechnology' should come in at $3.29 billion. The estimate suggests a change of +7.9% year over year.
The collective assessment of analysts points to an estimated 'Net Sales- Orthopaedics and Spine- Knees' of $604.67 million. The estimate indicates a change of +9.5% from the prior-year quarter.
The consensus estimate for 'Net Sales- Orthopaedics and Spine- Spine' stands at $309.09 million. The estimate indicates a year-over-year change of +4.1%.
It is projected by analysts that the 'Geographic Revenue- International' will reach $1.49 billion. The estimate indicates a change of +10.8% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenue- United States' reaching $4.11 billion. The estimate indicates a year-over-year change of +6.5%.
Based on the collective assessment of analysts, 'Net Sales- Orthopaedics and Spine- United States' should arrive at $1.60 billion. The estimate suggests a change of +3% year over year.
Analysts predict that the 'Net Sales- Orthopaedics and Spine- Trauma and Extremities- United States' will reach $596.86 million. The estimate points to a change of +5.6% from the year-ago quarter.
Analysts forecast 'Net Sales- Orthopaedics and Spine- Knees- United States' to reach $449.97 million. The estimate points to a change of +8.4% from the year-ago quarter.
Analysts expect 'Net Sales- Orthopaedics and Spine- Hips- United States' to come in at $253.04 million. The estimate points to a change of +5.9% from the year-ago quarter.
The average prediction of analysts places 'Net Sales- Orthopaedics and Spine- Spine- International' at $81.72 million. The estimate indicates a change of +7.5% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Orthopaedics and Spine- International' will reach $694.57 million. The estimate points to a change of +15.8% from the year-ago quarter.
View all Key Company Metrics for Stryker here>>>
Over the past month, shares of Stryker have returned +2.9% versus the Zacks S&P 500 composite's +2.5% change. Currently, SYK carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>